H1299 lung cancer cell lysate vaccine + Montanide ISA-51 VG

An investigational therapeutic cancer vaccine combination consisting of H1299 lung cancer cell lysate and the Montanide ISA-51 VG adjuvant. Developed by the National Cancer Institute (NCI), this vaccine is designed as an adjuvant therapy for patients with resected Stage IB-IIIA non-small cell lung cancer (NSCLC) who are PD-L1 negative. The H1299 cell lysate serves as the immunogenic component, providing a broad array of cancer-testis (CT) antigens to prime the immune system. Montanide ISA-51 VG, a water-in-oil emulsion adjuvant manufactured by Seppic, enhances the immune response by creating a depot effect at the injection site, allowing for the sustained release of antigens and the recruitment of antigen-presenting cells. The vaccine is administered subcutaneously with the goal of training the immune system to recognize and eliminate residual cancer cells to prevent disease recurrence.

Other names

H1299 lung cancer cell vaccineH-1299 lung cancer cell vaccineH 1299 lung cancer cell vaccineH1299 cell lysate vaccineH-1299 cell lysate vaccineH 1299 cell lysate vaccine